Chapter 22: Emerging Treatments for Psychiatric Disorders

Ketamine represents a paradigm shift in depression treatment by modulating glutamatergic neurotransmission through NMDA receptor antagonism, producing rapid-onset therapeutic effects distinct from traditional monoamine-based antidepressants. Psychedelic compounds including psilocybin, MDMA, and lysergic acid diethylamide are emerging from rigorous clinical investigations as promising interventions for treatment-resistant depression and post-traumatic stress disorder, with mechanisms potentially involving serotonergic pathway modulation and neuroplasticity enhancement. The role of cannabis in psychiatric care remains contested despite growing clinical interest in cannabinoid-based approaches for anxiety and trauma-related conditions, reflecting the current gap between patient interest and robust empirical validation. Anti-inflammatory pharmacological agents such as nonsteroidal anti-inflammatory drugs, statins, and omega-3 fatty acids demonstrate potential utility in mood disorder management by targeting neuroinflammatory pathways implicated in depression pathophysiology. The chapter emphasizes critical discontinuation protocols for psychotropic medications, highlighting how abrupt cessation precipitates withdrawal syndromes, relapse risk, and potential treatment resistance particularly with lithium salts and certain antidepressant classes. Gradual tapering strategies mitigate adverse discontinuation effects and preserve long-term treatment efficacy. Additionally, the chapter addresses perinatal considerations regarding maternal psychotropic medication exposure and neonatal adaptation outcomes, recognizing the complex risk-benefit analysis required when treating pregnant or nursing patients with psychiatric illness. These emerging approaches collectively represent the expanding therapeutic armamentarium available to clinicians while underscoring the necessity of individualized treatment planning and evidence-informed medication management.